Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SHE:301211)
12.05
-0.38 (-3.06%)
Apr 9, 2026, 3:04 PM CST
SHE:301211 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | 447.66 | 543.21 | 1,694 | 1,858 | 1,860 |
Trading Asset Securities | 1,107 | 1,094 | 129.4 | 103.98 | - |
Cash & Short-Term Investments | 1,555 | 1,637 | 1,824 | 1,962 | 1,860 |
Cash Growth | -5.00% | -10.26% | -7.05% | 5.50% | 438.28% |
Accounts Receivable | 91.47 | 75.53 | 75.08 | 127.47 | 161.05 |
Other Receivables | 4.15 | 3.8 | 2.66 | 1.35 | 3.09 |
Receivables | 95.62 | 79.33 | 77.74 | 128.82 | 164.14 |
Inventory | 122.68 | 137.85 | 173.8 | 114.7 | 89.5 |
Other Current Assets | 18.37 | 20.67 | 23.59 | 21.21 | 15.67 |
Total Current Assets | 1,792 | 1,875 | 2,099 | 2,227 | 2,129 |
Property, Plant & Equipment | 525.89 | 527.75 | 361.99 | 184.8 | 131.7 |
Long-Term Investments | 10.38 | 9.64 | - | - | - |
Other Intangible Assets | 66.83 | 68.94 | 71.07 | 73.27 | 66.67 |
Long-Term Deferred Tax Assets | 2.36 | 2.05 | 2.19 | 2.39 | 1.52 |
Long-Term Deferred Charges | 4.38 | 1.05 | 1.33 | - | - |
Other Long-Term Assets | 0.43 | 4.61 | 11.03 | 11.47 | 1.24 |
Total Assets | 2,402 | 2,489 | 2,547 | 2,499 | 2,330 |
Accounts Payable | 72.27 | 116.04 | 117.71 | 82.62 | 36.13 |
Accrued Expenses | 13.43 | 14.99 | 12.92 | 11.64 | 8.86 |
Current Portion of Long-Term Debt | 1.13 | - | - | - | - |
Current Portion of Leases | - | 1.59 | 1.51 | 0.97 | - |
Current Income Taxes Payable | 4.66 | 3.13 | 14.27 | 18.14 | 12.84 |
Current Unearned Revenue | 9.15 | 11.87 | 15.01 | 69.72 | 6.34 |
Other Current Liabilities | 13.9 | 16.76 | 13.73 | 25.82 | 38.84 |
Total Current Liabilities | 114.55 | 164.38 | 175.14 | 208.91 | 103.01 |
Long-Term Leases | 2.01 | 3.62 | 5.15 | 6.43 | - |
Long-Term Unearned Revenue | 1.96 | 2.04 | 2.1 | 0.22 | 0.28 |
Long-Term Deferred Tax Liabilities | 10.13 | 8.92 | 7.49 | 6.7 | 4.24 |
Total Liabilities | 128.65 | 178.97 | 189.89 | 222.26 | 107.53 |
Common Stock | 417.6 | 288 | 288 | 240 | 240 |
Additional Paid-In Capital | 1,627 | 1,757 | 1,757 | 1,805 | 1,805 |
Retained Earnings | 228.39 | 265.48 | 312.17 | 232.06 | 178.26 |
Comprehensive Income & Other | 0.33 | -0.3 | - | - | - |
Total Common Equity | 2,273 | 2,310 | 2,357 | 2,277 | 2,223 |
Shareholders' Equity | 2,273 | 2,310 | 2,357 | 2,277 | 2,223 |
Total Liabilities & Equity | 2,402 | 2,489 | 2,547 | 2,499 | 2,330 |
Total Debt | 3.13 | 5.22 | 6.66 | 7.4 | - |
Net Cash (Debt) | 1,552 | 1,632 | 1,817 | 1,955 | 1,860 |
Net Cash Growth | -4.89% | -10.21% | -7.04% | 5.10% | 438.28% |
Net Cash Per Share | 3.56 | 3.93 | 4.34 | 4.71 | 5.97 |
Filing Date Shares Outstanding | 489.53 | 417.6 | 417.6 | 417.6 | 417.6 |
Total Common Shares Outstanding | 489.53 | 417.6 | 417.6 | 417.6 | 417.6 |
Working Capital | 1,677 | 1,710 | 1,924 | 2,018 | 2,026 |
Book Value Per Share | 4.64 | 5.53 | 5.64 | 5.45 | 5.32 |
Tangible Book Value | 2,206 | 2,241 | 2,286 | 2,203 | 2,156 |
Tangible Book Value Per Share | 4.51 | 5.37 | 5.47 | 5.28 | 5.16 |
Buildings | - | 257.27 | 114.69 | 107.54 | 103.36 |
Machinery | - | 405.47 | 185.73 | 180.96 | 173.8 |
Construction In Progress | - | 53.5 | 228.77 | 51.56 | 2.17 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.